^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Colorectal Cancer
    Drug:Mvasi (bevacizumab-awwb) (VEGF-A inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    New
    Source:
    FDA
    Excerpt:
    MVASI is a vascular endothelial growth factor inhibitor indicated for the treatment of...Metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first or second-line treatment
    Secondary therapy:
    5-fluorouracil
    Evidence Level:
    Sensitive: A1 - Approval
    New
    Source:
    FDA
    Excerpt:
    MVASI is a vascular endothelial growth factor inhibitor indicated for the treatment of...Metastatic colorectal cancer, in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for second-line treatment in patients who have progressed on a first-line bevacizumab product-containing regimen
    Secondary therapy:
    oxaliplatin